CLINICAL TRIALS PROFILE FOR ARIPIPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for ARIPIPRAZOLE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00014001 ↗ | CATIE- Schizophrenia Trial | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2000-12-01 | The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate. |
| NCT00036101 ↗ | Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2002-02-01 | The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder. |
| NCT00036114 ↗ | Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2000-03-01 | The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type. |
| NCT00036127 ↗ | Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2/Phase 3 | 2002-04-01 | Study to learn if the alternate formulation is effective in agitated schizophrenic patients |
| NCT00036348 ↗ | Study of Aripiprazole in Patients With a History of Bipolar Disorder | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2000-03-01 | The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder. |
| NCT00036361 ↗ | Broad Effectiveness: Study With Aripiprazole | Completed | Otsuka America Pharmaceutical | Phase 3 | 2002-07-01 | The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARIPIPRAZOLE
Condition Name
Clinical Trial Locations for ARIPIPRAZOLE
Trials by Country
Clinical Trial Progress for ARIPIPRAZOLE
Clinical Trial Phase
Clinical Trial Sponsors for ARIPIPRAZOLE
Sponsor Name
